Abstract
Background: Chronic Bronchitis (CB) is a recurrent and persistent pulmonary inflammation disease.Growing evidence suggests an association between CB and Anti-neutrophil Cytoplasmic Antibody-associatedGlomerulonephritis (ANCA-GN). However, the precise mechanisms underlying their association remainunclear.
Aims: The purpose of this study was to further explore the molecular mechanism of the occurrence of chronicbronchitis (CB) associated with anti-neutrophil cytoplasmic antibody-associated glomerulonephritis (ANCA-GN).
Objective: Our study aimed to investigate the potential shared pathogenesis of CB-associated ANCA-GN.
Methods: Datasets of ANCA (GSE108113 and GSE104948) and CB (GSE151052 and GSE162635) were obtainedfrom the Gene Expression Omnibus (GEO) datasets. Firstly, GSE108113 and GSE151052 were analyzedto identify common differentially expressed genes (DEGs) by Limma package. Based on commonDEGs, protein-protein interaction (PPI) network and functional enrichment analyses, including GO, KEGG,and GSEA, were performed. Then, hub genes were identified by degree algorithm and validated inGSE104948 and GSE162635. Further PPI network and functional enrichment analyses were performed on hubgenes. Additionally, a competitive ceRNA network was constructed through miRanda and spongeScan. Transcriptionfactors (TFs) were predicted and verified using the TRRUST database. Furthermore, the CIBERSORTalgorithm was employed to explore immune cell infiltration. The Drug Gene Interaction Database(DGIDB) was utilized to predict small-molecular compounds of CB and ANCA-GN.
Results: A total of 963 DEGs were identified in the integrated CB dataset, and 610 DEGs were identified inthe integrated ANCA-GN dataset. Totally, we identified 22 common DEGs, of which 10 hub genes (LYZ, IRF1,PIK3CG, IL2RG, NT5E, ARG2, HBEGF, NFATC2, ALPL, and FKBP5) were primarily involved in inflammationand immune responses. Focusing on hub genes, we constructed a ceRNA network composed of323 miRNAs and 348 lncRNAs. Additionally, five TFs (SP1, RELA, NFKB1, HIF1A, and SP3) were identifiedto regulate the hub genes. Furthermore, immune cell infiltration results revealed immunoregulation in CBand ANCA-GN. Finally, some small-molecular compounds (Daclizumab, Aldesleukin, and NT5E) were predictedto predominantly regulate inflammation and immunity, especially IL-2.
Conclusion: Our study explores the inflammatory-immune pathways underlying CB-associated ANCA-GNand emphasizes the importance of NETs and lymphocyte differentiation, providing novel insights into theshared pathogenesis and therapeutic targets.
Keywords: Chronic bronchitis, anti-neutrophil cytoplasmic antibody, crescent glomerulonephritis, vasculitis, bioinformatics, differentially expressed genes.
« Previous Next »
Download Options
Rights & Permissions Print Cite
Current Pharmaceutical Design
Title:Exploration of the Shared Gene Signatures and Molecular Mechanismsbetween Chronic Bronchitis and Antineutrophil CytoplasmicAntibody-associated Glomerulonephritis: Evidence from Transcriptome Data
Volume: 30 Issue: 25
Author(s): Xiaojing Cai, Yueqiang Li, Qingquan Liu, Xiang Gao and Junhua Li*
Affiliation:
- Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan,China
Keywords: Chronic bronchitis, anti-neutrophil cytoplasmic antibody, crescent glomerulonephritis, vasculitis, bioinformatics, differentially expressed genes.
Abstract:
Background: Chronic Bronchitis (CB) is a recurrent and persistent pulmonary inflammation disease.Growing evidence suggests an association between CB and Anti-neutrophil Cytoplasmic Antibody-associatedGlomerulonephritis (ANCA-GN). However, the precise mechanisms underlying their association remainunclear.
Aims: The purpose of this study was to further explore the molecular mechanism of the occurrence of chronicbronchitis (CB) associated with anti-neutrophil cytoplasmic antibody-associated glomerulonephritis (ANCA-GN).
Objective: Our study aimed to investigate the potential shared pathogenesis of CB-associated ANCA-GN.
Methods: Datasets of ANCA (GSE108113 and GSE104948) and CB (GSE151052 and GSE162635) were obtainedfrom the Gene Expression Omnibus (GEO) datasets. Firstly, GSE108113 and GSE151052 were analyzedto identify common differentially expressed genes (DEGs) by Limma package. Based on commonDEGs, protein-protein interaction (PPI) network and functional enrichment analyses, including GO, KEGG,and GSEA, were performed. Then, hub genes were identified by degree algorithm and validated inGSE104948 and GSE162635. Further PPI network and functional enrichment analyses were performed on hubgenes. Additionally, a competitive ceRNA network was constructed through miRanda and spongeScan. Transcriptionfactors (TFs) were predicted and verified using the TRRUST database. Furthermore, the CIBERSORTalgorithm was employed to explore immune cell infiltration. The Drug Gene Interaction Database(DGIDB) was utilized to predict small-molecular compounds of CB and ANCA-GN.
Results: A total of 963 DEGs were identified in the integrated CB dataset, and 610 DEGs were identified inthe integrated ANCA-GN dataset. Totally, we identified 22 common DEGs, of which 10 hub genes (LYZ, IRF1,PIK3CG, IL2RG, NT5E, ARG2, HBEGF, NFATC2, ALPL, and FKBP5) were primarily involved in inflammationand immune responses. Focusing on hub genes, we constructed a ceRNA network composed of323 miRNAs and 348 lncRNAs. Additionally, five TFs (SP1, RELA, NFKB1, HIF1A, and SP3) were identifiedto regulate the hub genes. Furthermore, immune cell infiltration results revealed immunoregulation in CBand ANCA-GN. Finally, some small-molecular compounds (Daclizumab, Aldesleukin, and NT5E) were predictedto predominantly regulate inflammation and immunity, especially IL-2.
Conclusion: Our study explores the inflammatory-immune pathways underlying CB-associated ANCA-GNand emphasizes the importance of NETs and lymphocyte differentiation, providing novel insights into theshared pathogenesis and therapeutic targets.
Export Options
About this article
Cite this article as:
Cai Xiaojing, Li Yueqiang, Liu Qingquan, Gao Xiang and Li Junhua*, Exploration of the Shared Gene Signatures and Molecular Mechanismsbetween Chronic Bronchitis and Antineutrophil CytoplasmicAntibody-associated Glomerulonephritis: Evidence from Transcriptome Data, Current Pharmaceutical Design 2024; 30 (25) . https://dx.doi.org/10.2174/0113816128297623240521070426
DOI https://dx.doi.org/10.2174/0113816128297623240521070426 | Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher | Online ISSN 1873-4286 |
About this journal
Call for Papers in Thematic Issues
30 July, 2024
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis andstreptomycin have enabled an appropriate diagnosis and an effective treatment oftuberculosis (TB). Since then, many newer diagnosis methods and drugs have beensaving millions of lives. Despite advances in the past, TB is still a leading cause ofinfectious disease mortality ...read more
Guest Editor(s): Dr. M Pinheiro
03 December, 2024
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Guest Editor(s): Dr. Carlo Cervellati
18 September, 2024
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Guest Editor(s): Dr. Sidharth Mehan
03 December, 2024
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Guest Editor(s): Dr. Ali Yadollahpour,
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
View More
Related Books
Drug Addiction Mechanisms in the Brain
The NLRP3 Inflammasome: An Attentive Arbiter of Inflammatory Response
Software and Programming Tools in Pharmaceutical Research
Objective Pharmaceutics: A Comprehensive Compilation of Questions and Answers for Pharmaceutics Exam Prep
Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems
Advanced Pharmacy
Plant-derived Hepatoprotective Drugs
The Role of Chromenes in Drug Discovery and Development
New Avenues in Drug Discovery and Bioactive Natural Products
Practice and Re-Emergence of Herbal Medicine
View More
Article Metrics
5
- About Journal
- Editorial Board
- Current Issue
- Volumes /Issues
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Guest Editor Guidelines
- Editorial Management
- Fabricating and Stating False Information
- Publishing Ethics and Rectitude
- Ethical Guidelines for New Editors
- Peer Review Workflow
- Reviewer Guidelines
- Peer Review Workflow
- Fabricating and Stating False Information
- Publishing Ethics and Rectitude
- Abstract Ahead of Print 0
- Article(s) in Press 32
- Free Online Copy
- Most Cited Articles
- Most Accessed Articles
- Editor's Choice
- Thematic Issues
- Open Access Articles
- Library Recommendation
- Trial Requests
- Advertise With Us
- Meet the Executive Guest Editor(s)
- Brand Ambassador
- New Journals 2023
- New Journals 2024
- Alert Subscription
- TOC Alert
© 2024 Bentham Science Publishers | Privacy Policy